Cargando…

RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease

OBJECTIVE: Receptor-interacting protein kinase 3 (RIPK3) is a key player in necroptosis execution and an emerging metabolic regulator, whose contribution to non-alcoholic fatty liver disease (NAFLD) is controversial. We aimed to clarify the impact of RIPK3 signalling in the pathogenesis of human and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Afonso, Marta B, Rodrigues, Pedro M, Mateus-Pinheiro, Miguel, Simão, André L, Gaspar, Maria M, Majdi, Amine, Arretxe, Enara, Alonso, Cristina, Santos-Laso, Alvaro, Jimenez-Agüero, Raul, Eizaguirre, Emma, Bujanda, Luis, Pareja, Maria Jesus, Banales, Jesus M, Ratziu, Vlad, Gautheron, Jeremie, Castro, Rui E, Rodrigues, Cecília M P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Hepatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8588316/ https://www.ncbi.nlm.nih.gov/pubmed/33361348 http://dx.doi.org/10.1136/gutjnl-2020-321767

Ejemplares similares

Non-parenchymal TREM-2 protects the liver from immune-mediated hepatocellular damage
por: Perugorria, Maria J, et al.
Publicado: (2019)

TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms
por: Esparza-Baquer, Aitor, et al.
Publicado: (2021)

The scaffold-dependent function of RIPK1 in experimental non-alcoholic steatohepatitis
por: Pistorio, Valeria, et al.
Publicado: (2022)

Adiponectin, Leptin, and IGF-1 Are Useful Diagnostic and Stratification Biomarkers of NAFLD
por: Marques, Vanda, et al.
Publicado: (2021)

Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease
por: Nascimbeni, Fabio, et al.
Publicado: (2016)

Tonicity-responsive enhancer-binding protein promotes hepatocellular carcinogenesis, recurrence and metastasis
por: Lee, Jun Ho, et al.
Publicado: (2019)

The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma
por: Lewinska, Monika, et al.
Publicado: (2021)

RIPK3 dampens mitochondrial bioenergetics and lipid droplet dynamics in metabolic liver disease
por: Afonso, Marta B., et al.
Publicado: (2023)

Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity
por: Poynard, Thierry, et al.
Publicado: (2015)

Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort
por: Welzel, Tania M, et al.
Publicado: (2016)

Changes in gastric mucosal microbiota in gastric carcinogenesis: a systematic review protocol
por: Ji, Ruoyu, et al.
Publicado: (2021)

Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease
por: Sayiner, Mehmet, et al.
Publicado: (2016)

Novel pathomechanism for spontaneous bacterial peritonitis: disruption of cell junctions by cellular and bacterial proteases
por: Haderer, Marika, et al.
Publicado: (2022)

Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD)
por: Golabi, Pegah, et al.
Publicado: (2018)

Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis
por: Banales, Jesus M., et al.
Publicado: (2019)

STAT4-associated natural killer cell tolerance following liver transplantation
por: Jamil, K M, et al.
Publicado: (2017)

Prolonged dual hypothermic oxygenated machine preservation (DHOPE-PRO) in liver transplantation: study protocol for a stage 2, prospective, dual-arm, safety and feasibility clinical trial
por: Brüggenwirth, Isabel M A, et al.
Publicado: (2022)

Prevention of hepatic encephalopathy by administration of rifaximin and lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt (TIPS): a multicentre randomised, double blind, placebo controlled trial (PEARL trial)
por: de Wit, K, et al.
Publicado: (2020)

Pitfalls in diagnosis and treatment of alveolar echinococcosis: a sentinel case series
por: Stojkovic, M, et al.
Publicado: (2015)

Cleavage of the IPS-1/Cardif/MAVS/VISA does not inhibit T cell-mediated elimination of hepatitis C virus non-structural 3/4A-expressing hepatocytes
por: Ahlén, G, et al.
Publicado: (2009)

Prevalence, risk factors and metabolic profile of the non-obese and obese non-alcoholic fatty liver disease in a rural community of South Asia
por: Rahman, M Masudur, et al.
Publicado: (2020)

The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis
por: Poynard, Thierry, et al.
Publicado: (2019)

Effect of pravastatin on the survival of patients with advanced gastric cancer
por: Bujanda, Luis, et al.
Publicado: (2015)

Non-selective β-blockers in advanced cirrhosis: a critical review of the effects on overall survival and renal function
por: Blasco-Algora, Sara, et al.
Publicado: (2016)

Prevalence of non-alcoholic fatty liver disease in overweight and obese children seeking ambulatory healthcare in Nairobi, Kenya
por: Mburu, Anne Njeri, et al.
Publicado: (2023)

An educational tool for the prophylaxis of hepatic encephalopathy
por: Garrido, Maria, et al.
Publicado: (2017)

Insight Into the Function of RIPK4 in Keratinocyte Differentiation and Carcinogenesis
por: Xu, Jing, et al.
Publicado: (2020)

Efficacy of antiviral therapy in patients with post-hepatitis C liver cirrhosis: is hyperuricaemia a potential adverse effect?
por: Elsayed, Amr, et al.
Publicado: (2020)

Prevalence and trends of transfusion transmissible infections among blood donors in Basra, Iraq
por: Mohammed, Khairallah A S, et al.
Publicado: (2023)

A novel prognostic model for transplant-free survival in primary sclerosing cholangitis
por: de Vries, Elisabeth M, et al.
Publicado: (2018)

Costs and cost-effectiveness of different follow-up schedules for detection of occupational hepatitis C virus infection
por: Deuffic-Burban, S, et al.
Publicado: (2008)

The human liver microenvironment shapes the homing and function of CD4(+) T-cell populations
por: Wiggins, Benjamin G, et al.
Publicado: (2022)

GM-CSF drives myelopoiesis, recruitment and polarisation of tumour-associated macrophages in cholangiocarcinoma and systemic blockade facilitates antitumour immunity
por: Ruffolo, Luis I, et al.
Publicado: (2022)

Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection
por: Janssen, Harry L A, et al.
Publicado: (2023)

Defining the key intrahepatic gene networks in HCV infection driven by sex
por: Marchi, Emanuele, et al.
Publicado: (2023)

Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C
por: Colombo, M, et al.
Publicado: (2014)

Rifaximin versus norfloxacin for prevention of spontaneous bacterial peritonitis: a systematic review
por: Sidhu, Gurpartap S, et al.
Publicado: (2017)

Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis
por: Harms, Maren H, et al.
Publicado: (2020)

Bacteraemia, sepsis and antibiotic resistance in Australian patients with cirrhosis: a population-based study
por: Johnson, Amy L, et al.
Publicado: (2021)

Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study
por: Welzel, Tania M, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_hpg2muof68jq9868cg65rmjne4